RU2445066C1 - Method of treating facial nerve neuropathy - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely - to neurology. A method involves intracutaneous introductions of cerebrolysin by a single injection method. At first cerebrolysin is introduced in biologically active points VG22-VG27, VB1, VB2, VB10, VB13-VB16, E2, E3, VC24, GI19, GI20, JG18, JG19, TR21-TR23, V1-V6. Then it is injected in skin along affected reflex therapy meridians, affected muscles involved in a pathology. A total dose injected at one procedure makes 0.3 to 1.0 ml according to the patient's age. The procedures are once a day. Course of treatment is 10-15 days.

EFFECT: method reduces procedure injures ensured by controlling a depth of needle penetration and reduces length of procedure, provides minimised psychological affect of the procedure.

3 ex

Description

The invention relates to medicine, namely to neurology, and can be used to treat facial neuropathy.

From the practice of medicine, a method is known for treating facial neuropathy by injecting cerebrolysin into the paretic muscle with a syringe (Skvortsov IA, “Cerebral Palsy and Other Disorders of Neurological Development, treatment principles according to the Skvortsov-Osipenko method” - M. 1995).

There is a method of treating facial neuropathy based on physiotherapeutic effects: paraffin, ozokerite, UHF in a low-temperature dose, ultrafon, a mastoid laser and exit points of the facial nerve, alternating magnetic field (Dorofeeva L.K., Edomsky A.K. “Application experience metameric administration of cerebrolysin according to the Skvortsov-Osipenko technique for severe facial neuropathies ”(Omsk State Medical Academy, UZ OD KB) // Mother and Child in Kuzbass, No. 1 (20), 2005, p. 37), and massage is also used facial neuritis (Du Brovsky V.I. “Types of Massage.” - M.: Young Guard, 1993, p.183-184).

However, the known analogues have disadvantages:

- the introduction of drugs with a syringe cannot give a precisely calibrated dosage of the drug;

- injection of the drug does not provide control of the depth of the needle, which means there is no guarantee of the accuracy of the drug in the BAP;

- palpation technique adversely affects the behavior of the patient (child);

- with physiotherapy with paraffin, especially in children of 1 year of age, it is difficult to fix and hold paraffin applications;

- there are a large number of contraindications for physiotherapy (fever, acute respiratory infections, etc.);

- skin damage is a contraindication to massage.

A known method of treating primary facial neuropathies of the facial nerve (Patent No. 2156122, publ. 2000.09.20), which consists in the introduction of hydrocortisone succinate cyano-cobalamin in biologically active points.

However, this prototype has the following disadvantages:

- the introduction of the drug by syringe palpation does not give the accuracy of the administered dosage of the drug;

- there is no control of the depth of insertion of the needle and tracking the accuracy of getting the drug into biologically active points;

- palpation of the method of drug administration causes psychological rejection of the method in children.

The present invention is aimed at increasing the efficiency of drug administration (dosed injection of drugs), reducing the morbidity by controlling the depth of penetration of the needle and reducing the time of the procedure, which entails minimizing the psychological affect of the procedure.

The specified technical result is achieved by the fact that the patient is injected with cerebrolysin intradermally by a mechanical injection method in a single injection into the biologically active points VG22-VG27, VB1, VB2, VB10, VB13-VB16, E2, EZ, VC24, GI19, GI20, JG18, JG19, TR21- TR23, V1-V6, then repeatedly to the skin along the affected reflexotherapy meridians and to the affected muscles involved in the pathological condition, in a total dose administered in one procedure to all of the listed points and zones, from 0.3 to 1.0 ml, depending on age patient 1 time per day for 10-15 days.

The effective bringing of the pharmaceutical product to the lesion site, the ability to make the pharmacoballing multiple, saturate the affected area as much as possible and affect any additional features of the disease course, individual variations of the pathology create more extensive possibilities for reducing the duration of the disease, stimulate the treatment process by summing up the effect of the reflex response to exposure to a biologically active point with cerebrolysin. The proposed method uses a full-automatic meso-injector "Pistor-4" (made in France), in connection with which a high degree of analgesic effect is achieved due to the introduction of microdoses of the drug. The injection rate is up to 200 injections per minute.

When a patient is diagnosed, cerebrolysin is injected with a single mechanical injection into biologically active points, and repeatedly into tissues and muscles.

The proposed method was successfully tested for 127 patients in the Regional Children's Clinical Hospital in Astrakhan, the 2nd city children's hospital in Astrakhan, UDCA of the Astrakhan State Medical Academy during 2005-2010.

Below are the results of testing.

Example 1. Patient 25 years. Upon admission, paralysis of the facial muscles, the impossibility of wrinkling the forehead on the right, are noted. The nasolabial fold is smoothed on the affected side, the mouth will be pulled to the left side. On the sore side, the mouth is fixed, saliva flows from the corner of the mouth due to poor closing of the lips. The patient cannot blow out the candle, whistle. When asked to close their eyes, the eyelids do not close on the sore side, the sclera is visible through an open slit, lacrimation is noted.

Diagnosis: facial neuropathy due to hypothermia.

Treatment: mechanical pharmacopuncture by means of a PISTOR4 meso-injector. Cerebrolysin 1.0 at points: VG22-VG27, VB1, VB2, VB10, VB13-VB16, E2, E3, VC24, GI19, GI20, JG18, JG19, TR21-TR23, V1-V6, as well as into the skin along the way the affected reflexotherapy meridians and the affected muscles involved in the pathological condition (for the entire procedure, the volume of the drug is 1.0 ml).

Positive dynamics was noted on the second day. The patient notes the appearance of sensitivity, there is a movement of the angle of the mouth of the paralyzed side. On the fourth day, the patient slightly inflates the cheek from the paralyzed side, a tendency to wrinkling his forehead appears. On the fifth day, improvement in the functioning of facial muscles is noted, the patient smiles on the affected side. On the eighth day, the patient inflates the cheek from the affected side. On the tenth day, the patient completely recovered the volume of folds on her forehead when wrinkling. On the fifteenth day, complete restoration of the muscles of the facial muscles is noted. The eyelids are completely closed, the sensitivity is not broken. Dosage 1.0 daily once for 15 days.

Example 2. Patient, 2 months. He was admitted for treatment with complaints of smoothness of the nasolabial fold on the left, the angle of the mouth was lowered. Asymmetry of the face is especially noticeable when crying and screaming. The general condition is not broken, the dream is saved. The acts of sucking and swallowing are not changed. Marked lagophthalmus is noted. A mechanical injection pharmacopuncture was performed at the points: VG22-VG27, VB1, VB2, VB10, VB13-VB16, E2, E3, VC24, GI19, GI20, JG18, JG19, TR21-TR23, V1-V6, as well as into the skin along the way the affected reflexotherapy meridians and the affected muscles involved in the pathological condition at a dose of 0.3 ml for the entire procedure per day for 10 days. After treatment, all pathological symptoms disappeared.

Example 3. The patient is 9 years old. He came in with complaints of paralysis of facial muscles (Bell's paralysis): on the side of the paralysis, the eyelids are wider than on the healthy side, if you want to close your eye - the gap between the eyelids. The patient cannot frown, frown on the right. The nasolabial fold on the affected side is flattened. The mouth gap is pulled to the healthy side. The child became acutely ill when, after hypothermia, the above symptoms developed. The patient can not puff out his cheek on the right, the whistle does not work.

Treatment: mechanical pharmacopuncture by means of a PISTOR4 meso-injector. Cerebrolysin 0.5 ml for the entire procedure once a day for 13 days at the points: VG22-VG27, VB1, VB2, VB10, VB13-VB16, E2, E3, VC24, GI19, GI20, JG18, JG19, TR21-TR23 , V1-V6, as well as into the skin along the affected reflexotherapy meridians and into the affected muscles involved in the pathological condition. After 13 days of treatment, the complaints were leveled.

A year later, the former patients were examined. Relapse of the disease was not observed.

The proposed method achieves the following technical result:

- increasing the efficiency of the introduction of drugs (dosed injection of drugs),

- reducing trauma by controlling the depth of penetration of the needle;

- reducing the time of the procedure, which entails minimizing the psychological affect of the procedure.

Claims (1)

A method of treating facial neuropathy by administering cerebrolysin intracutaneously by mechanical injection by a single injection into biologically active points VG22-VG27, VB1, VB2, VB10, VB13-VB16, E2, E3, VC24, GI19, GI20, JG18, JG19, TR21 -23 V1-V6, then repeatedly to the skin along the affected reflexotherapy meridians, to the affected muscles involved in the pathological condition, in a total dose administered in one procedure to all of the listed points and zones, from 0.3 to 1.0 ml, depending from the age of the patient, 1 time per day, for 10-15 days.